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LETTERS
Tokyo-172 BCG 
Vaccination  
Complications,  
Taiwan
To the Editor: BCG (Mycobacte-
rium bovis BCG) is a vaccine for pre-
venting childhood tuberculosis (TB), 
especially military and meningeal TB. 
Because  Taiwan  has  an  annual  TB 
incidence  rate  of  ≈70  cases/100,000 
persons,  the  National  Immunization 
Program has included neonatal BCG 
vaccination since 1965. The coverage 
rate has remained at 97% since 2001. 
According to the Taiwan Tuberculosis 
Registry, the median rate of TB infec-
tions diagnosed in patients <10 years 
of age during 2005–2007 was 0.39% 
(60 cases) (1). The risk of developing 
childhood extrapulmonary TB without 
lung  involvement  is  highest  among 
children <5 years of age.
In  1965,  the  World  Health  Or-
ganization  registered  freeze-dried 
Tokyo-172 seed lot as an international 
reference  vaccine  strain  (2).  Tokyo-
172 BCG is currently used in Taiwan, 
Japan, and South Korea. The vaccine 
is recommended as less reactogenic. 
Because intradermal injection is rec-
ognized as a more effective BCG ad-
ministration route (3), it is practiced 
in Taiwan, while a multiple puncture 
method  is  used  in  Japan  and  South 
Korea. In addition, 10% BCG (Danish 
strain) vaccinations for infants are ad-
ministrated intracutaneously in South 
Korea (4). Although BCG is effective 
in preventing progressive primary TB, 
adverse  reactions  to  the  vaccine  do 
occur. A systemic review of adverse 
reactions has been established in Ja-
pan (5) but not in South Korea (4) and 
Taiwan (6).
During 1951–2004, a total of 39 
cases of severe adverse vaccine reac-
tions were reported in Japan, with an 
incidence rate of 0.182 cases of reac-
tions/million vaccinations. Of the 39 
cases, 27 patients (69.2%) had bone 
and joint involvement, and 13 (33.3%) 
had  primary  immunodeficiency  (4). 
One  patient  had  both  complications. 
The  BCG  vaccine  was  initially  pro-
duced  in Taiwan  using  Pasteur-1173 
P2  strain  (0.025  mg/0.1mL)  and 
changed to the less reactogenic Tokyo-
172 strain (0.05 mg/0.1 mL) in 1979. 
From 1998 through 2007, 14 patients 
applied for compensation through the 
vaccine injury compensation program 
for BCG-caused adverse reaction, and 
6  claims  were  confirmed.  Of  the  6 
confirmed BCG complications cases, 
5 patients had humeral or sternal os-
teomyelitis and 1 patient died from a 
disseminated BCG infection. Accord-
ingly, in 2002–2006 the risk for BCG 
osteitis/osteomyelitis and disseminat-
ed BCG infection was 3.68 and 0.9 per 
million, respectively (6). Incidence of 
severe complications was higher than 
that documented in Japan.
Because Taiwan  lacks  diagnosis 
and  postmarketing  surveillance  sys-
tem, BCG-related complications might 
be  underreported. As  part  of  initiat-
ing  a  comprehensive  adverse  events 
surveillance, a laboratory program to 
differentiate M. bovis BCG from other 
species  of  the  M.  tuberculosis  com-
plex was established to monitor local 
adverse events (injection-site abscess, 
lymphadenitis) and severe complica-
tions  (suppurative  lymphadentitis, 
BCG  osteitis/osteomyelitis,  and  dis-
seminated BCG infection) among vac-
cinated children.
During  2005–2007,  19  clinical 
specimens (6 biopsy samples and 13 
bacterial isolates) of suspected BCG-
infection  childhood  TB  cases  were 
sent to the Taiwan Centers for Disease 
Control.  To  differentiate  among  M. 
tuberculosis, M. bovis, and M. bovis 
BCG,  DNA  samples  were  initially 
screened using a GenoType kit (Hain 
Lifescience  GmbH,  Nehren,  Germa-
ny), multiplex PCR (7), and pncA se-
quencing (8). In addition, spoligotyp-
ing was performed with a commercial 
kit (Isogen Bioscience BV, Maarssen, 
the Netherlands). An additional multi-
plex PCR (9) was used to differentiate 
vaccine strains. Medical charts were 
reviewed to determine sites of involve-
ment and severity of complications.
Of  the  19  patients,  1  (5.3%),  2 
(10.5%),  15  (78.9%),  and  1  (5.3%) 
were  infected  with  M.  tuberculosis 
complex,  M.  tuberculosis,  M.  bovis 
BCG, and M. abscessus, respectively. 
All identified M. bovis BCG isolates 
had the same spoligotype as the To-
kyo-172  vaccine  strain.  The  median 
age of BCG-related complication pa-
tients was 2 years (range 1–9 years), 
and  the  male:female  ratio  was  1.5. 
Of  the  15  M.  bovis  BCG–infected 
patients, 14 had extrapulmonary sites 
of involvement, including 8 bone and 
joint, 3 suppurative lymphadenitis in 
axillary lymph node, 2 subcutaneous 
abscess away from the injection site, 1 
injection-site abscess, and 1 dissemi-
nated BCG infection (Table).
According  to  an  international 
survey, the estimated rate of osteitis/
osteomyelitis  is  1–700/1,000,000 
vaccinated newborns or infants with 
different strain-derived BCG (10). In 
Taiwan,  the  estimated  incidence  of 
BCG osteitis/osteomyelitis was 12.9 
cases  (8/621,853;  95%  confidence 
interval 4–21.8) per million vaccina-
tions  during  2005–2007.  Previously 
reported  complications  of  BCG  os-
teitis/osteomyelitis related to Tokyo-
172 strain might be underestimated. 
The  association  between  adminis-
tration  route  and  osteitis/osteomy-
elitis with Tokyo-172 BCG remains 
obscure. The potency and safety of 
BCG prepared from Tokyo-172 stain 
are under reevaluation as one of the 
action plans of National TB Program. 
The  stability  and  quality  control  of 
vaccines strain, production processes, 
and intradermal injection techniques 
are being reappraised.
Furthermore, a policy of enhanced 
childhood TB surveillance was imple-
mented in 2007, and clinicians were 
advised  to  send  clinical  specimens 
to the Centers for Disease Control in 
Taiwan  for  differential  diagnosis  of 
M. bovis BCG for patients <5 years of 
	 Emerging	Infectious	Diseases	•	www.cdc.gov/eid	•	Vol.	15,	No.	9,	September	2009	 1525 LETTERS
age. In particular, suspected childhood 
TB patients without an identifiable TB 
contact and with normal immune sta-
tus were subjected to further investiga-
tions.  Multidisciplinary  management, 
including enhanced laboratory diagno-
sis of atypical bony lesions in infants 
and children, is recommended for any 
suspected  TB  infection.  Once  BCG-
related infection is confirmed, medical 
treatment has to be consistent. 
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Reemergence  
of Bolivian  
Hemorrhagic Fever,   
2007–2008
To the Editor: Bolivian hemor-
rhagic fever (BHF) was first described 
in  1959  during  outbreaks  affecting 
isolated human communities in east-
ern Bolivia. However, it was not until 
1963 that the etiologic agent, Machupo 
virus, was isolated from the spleen of 
a patient who died from this disease 
(1). Although no cases were reported 
between 1976 and 1993, an outbreak 
occurred in 1994 and sporadic cases 
have been observed since then.
In February and March 2007, at 
least 20 suspected BHF cases (3 fatal) 
were reported to the El Servicio Depar-
tamental de Salud (SEDES) in Beni, 
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Table.	Characteristics	Mycobacterium bovis	BCG	complication	cases,	Taiwan,	2005–2007*	
Patient
no.
Sex/age	at	
diagnosis,	y	 Year	reported	 Specimen Diagnosis	and	site	of	involvement	
1 F/2 2005 Biopsy	sample	 BCG	osteitis/osteomyelitis,	right	ankle	
2 M/1 2005 Bacterial	isolate	 Subcutaneous	abscess,	left	anterior	chest	wall	
3 M/2 2005 Bacterial	isolate	 Severe	combined	immunodeficiency,	disseminated	BCGitis	
4 M/9 2005 Bacterial	isolate	 Suppurative	lymphadenitis	
5 F/1 2005 Bacterial	isolate	 Injection-site	abscess	
6 M/1 2005 Biopsy	sample	 Suppurative	lymphadenitis	
7 M/2 2006 Bacterial	isolate	 BCG	osteitis/osteomyelitis,	right	distal	femoris	
8 M/2 2006 Bacterial	isolate	 BCG	osteitis/osteomyelitis	
9 F/1 2006 Bacterial	isolate	 BCG	osteitis/osteomyelitis,	left	distal	femoris	
10 F/1 2006 Bacterial	isolate	 BCG	osteitis/osteomyelitis,	left	distal	radius	
11 F/2 2007 Bacterial	isolate	 BCG	osteitis/osteomyelitis,	right	knee	
12 M/1 2007 Bacterial	isolate	 Subcutaneous	abscess,	left	wrist	
13 M/2 2007 Biopsy	sample	 BCG	osteitis/osteomyelitis,	right	ankle	
14 F/1 2007 Bacterial	isolate	 Suppurative	lymphadentitis	
15 M/2 2007 Bacterial	isolate	 BCG	osteitis/osteomyelitis,	left	proximal	tibia	
*BCGitis,	disseminated	BCG	infection.	